You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRAF inhibitor

Showing 1 - 25 of 7,849
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial in Boston, Harrison, New York (Dabrafenib, Trametinib, Phenformin)

Active, not recruiting
  • Melanoma
  • Boston, Massachusetts
  • +2 more
Jun 14, 2022

BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,

Recruiting
  • BRAF NP_004324.2:p.V600E
  • +2 more
  • Duarte, California
  • +1 more
Jan 19, 2023

Melanoma (Skin), Skin Cancer, Skin Melanoma Trial in Tampa (Vemurafenib, Cobimetinib)

Recruiting
  • Melanoma (Skin)
  • +3 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Dec 30, 2022

Thyroid Carcinoma Trial in New York (Vemurafenib, serial 124I PET/CT, thyrotropin alpha)

Active, not recruiting
  • Thyroid Carcinoma
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 28, 2022

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the CNS

Recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +3 more
  • Scottsdale, Arizona
  • +2 more
Jan 4, 2023

Rechallenge of BRAF +/- MEK Inhibitors FollowingAdverse Event in

Active, not recruiting
  • Cancer
  • BRAF inhibitor
  • (no location specified)
Oct 13, 2021

Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma Trial in Houston, Salt Lake City (procedure, drug,

Recruiting
  • Thyroid Gland Anaplastic Carcinoma
  • Thyroid Gland Squamous Cell Carcinoma
  • Conventional Surgery
  • +5 more
  • Stanford, California
  • +5 more
Jan 26, 2023

BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,

Active, not recruiting
  • BRAF V600E Mutation Present
  • +9 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2022

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID

Active, not recruiting
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Non Small Cell Lung Cancer Trial (HLX208+HLX10)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • HLX208+HLX10
  • (no location specified)
Nov 30, 2022

CRC Trial in Shanghai (HLX208, Cetuximab Injection [Erbitux])

Recruiting
  • CRC
  • HLX208
  • Cetuximab Injection [Erbitux]
  • Shanghai, China
    Fudan University Affiliated Oncology Hospital
Dec 30, 2021

Cancer Harboring BRAF Alterations Trial (FORE8394, Cobicistat)

Not yet recruiting
  • Cancer Harboring BRAF Alterations
  • (no location specified)
Aug 15, 2022

Metastatic Colorectal Cancer, mCRC Trial in Shenyang (HLX208)

Recruiting
  • Metastatic Colorectal Cancer
  • mCRC
  • Shenyang, Liaoning, China
    Liaoning Cancer Hospital
May 1, 2022

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United States (Dabrafenib Mesylate, Tazemetostat

Recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Metastatic Melanoma
  • Dabrafenib Mesylate
  • +2 more
  • Atlanta, Georgia
  • +6 more
Nov 30, 2022

Hairy Cell Leukemia, Leukemia, Leukemia, Hairy Cell Trial in United States (Vemurafenib, Obinutuzumab)

Active, not recruiting
  • Hairy Cell Leukemia
  • +2 more
  • New Haven, Connecticut
  • +8 more
Feb 7, 2022

Brain Tumor, Primary Trial in Jinan (HLX208)

Recruiting
  • Brain Tumor, Primary
  • Jinan, Shandong, China
    Cancer Hospital Affiliated to Shandong first medical University
May 1, 2022

Melanoma Trial in Tampa (XL888, Vemurafenib)

Active, not recruiting
  • Melanoma
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Aug 18, 2022

Cancer, Cancer Metastatic, BRAF V600E Trial in Indianapolis (Abemaciclib, LY3214996)

Recruiting
  • Cancer
  • +6 more
  • Indianapolis, Indiana
    Indiana University Hospital / IU Simon Cancer Center
Jan 12, 2023

BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)

Terminated
  • BRAF V600E Mutation Present
  • +7 more
  • Boston, Massachusetts
  • +1 more
Mar 9, 2022

Solid Tumor Trial in Guangzhou (HLX 208)

Recruiting
  • Solid Tumor
  • HLX 208
  • Guangzhou, China
    Sun Yat-sen University Cancer Center
Jan 26, 2022

Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma Trial in Chapel Hill (BRAF inhibitor dabrafenib and MEK inhibitor

Completed
Has Results
  • Stage III Melanoma
  • +3 more
  • BRAF inhibitor dabrafenib and MEK inhibitor trametinib
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center, University of North Caro
Nov 3, 2020

Anaplastic Thyroid Cancer, ATC Trial in Shanghai (HLX208)

Recruiting
  • Anaplastic Thyroid Cancer
  • ATC
  • Shanghai, China
    Fudan University Affiliated Oncology Hospital
Dec 30, 2021

BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Tumor Trial in Houston (biological, drug, other)

Active, not recruiting
  • BRAF NP_004324.2:p.V600X
  • +6 more
  • Cetuximab
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Cancer Trial in Worldwide (Dabrafenib, Trametinib, Panitumumab)

Completed
Has Results
  • Cancer
  • Scottsdale, Arizona
  • +19 more
Sep 30, 2021

Langerhans Cell Histiocytosis, Erdheim-Chester Disease, LCH Trial in Beijing (HLX208)

Recruiting
  • Langerhans Cell Histiocytosis
  • +3 more
  • Beijing, China
    Peking Union Medical College Hospital
Dec 30, 2021